SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brad C. Dunlap who wrote (34)9/15/1996 9:45:00 AM
From: WWS   of 1762
 
Brad, besides Coulter another company competing for N.H. Lymphoma business is Immunomedics (IMMU). (P.S. I own both IDPH and IMMU). Following is an exerpt about IMMU's approach to N.H. Lymphoma, taken from a post of Josh Pleasure on the IMMU thread here on S.I.:

1. Non-Hodgkin's Lymphoma (NHL):
Currently, Gallium is the most commonly used radioisotope for imaging
of Lymphoma. Nuclear medicine plays a key role in following lymphoma
patients because standard imaging like CT scans cannot differentiate active
lymphoma from the scar tissue which results from treatment.
Unfortunately, not all lymphomas are "Gallium-avid" and therefore
Gallium scanning is not helpful. LymphoScan is a safe, effective
alternative to Gallium scanning with one key advantage as described below.

Dr. Goldenberg's article in Eur J Nucl Med 1992;19(6):385-6 elaborated on
an important advantage of LymphoScan over Gallium scanning.
Specifically, LymphoScan resulted in "excellent targeting of gallium-
negative sites in the liver and bone." This is extremely important because
often the only clue that a soft tissue lesion is active lymphoma as opposed to
treated, scarred lymphoma is its uptake of Gallium. LymphoScan
therefore offers a unique advantage. Treated lymphoma (scar) and active

Promising results for imaging with LymphoScan are also reported in
Cancer Research. 55(23 Suppl):5764s-5770s, 1995 Dec 1.

2. TREATMENT of Non-Hodgkin's Lymphoma:
When the same antibody used in LymphoScan ("LL2") is attached to a
more potent radioactive chemical, highly efficient and specific therapy of
non-Hodgkin's Lymphoma may be possible. Very promising results have
been reported. In the July 24, 1996 Press Release, Dr. Goldenberg stated,
"Clinical trials with the lymphoma therapeutic are progressing well, with
encouraging clinical responses being noted. Thus, we plan to develop both
an imaging/staging agent and its therapeutic partner."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News